BioSpace News Archive

NewAmsterdam Pharma Company N.V. announced the appointment of William H. Lewis, J.D., M.B.A., as Chair of its Board of Directors.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, outlined progress within its pipeline programs and key milestones for 2024.

Ardelyx, Inc. provided an update on the company’s progress in 2023 and initial expectations for 2024.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023, and issued 2024 financial guidance.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, will discuss the Company’s 2024 strategic priorities and anticipated milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, at 4:30 p.m. PST.

bluebird bio, Inc. (Nasdaq: BLUE) (the Company; bluebird) today announced updates to be presented at the 42nd Annual J.P. Morgan Healthcare conference including commercial launch progress, 2024 program milestones and financial outlook.

DexCom, Inc. today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.

Revance Therapeutics, Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.

Mind Medicine today provided a corporate update and outlook for 2024.

Novotech announced that it will have the largest ever presence at the J.P.Morgan Healthcare Conference in San Francisco, CA, USA, January 8-11, 2024.